复发及难治多发性骨髓瘤的药物治疗

Drug treatment of relapsed and refractory multipe myeloma

关键词:  多发性骨髓瘤  复发  难治  药物治疗

Key words:  multiple myeloma  relapse  refractory  drug therapy

摘要:

多发性骨髓瘤（multiple myeloma，MM）是一种浆细胞恶性克隆增殖性疾病，几乎所有患者最终都会进入难治或复发阶段，因而仍为不可治愈的恶性血液病。新一代的免疫调节剂、蛋白酶体抑制剂、单克隆抗体、去乙酰化酶抑制剂及信号通路抑制剂能够改善复发及难治MM的缓解率及生存期，但还需更加合理地联合传统药物、优化给药方式、提高生物相容性及降低造价成本。

Abstract:

Multiple myeloma (MM) is a cloning proliferation of plasma cell disease, which is still one of incurable malignant hematological diseases. Almost all the MM patients will eventually enter the stage of refractory or relapse, A new generation of immune modulators, protease inhibitors, monoclonal antibodies, to acetylation enzyme inhibitors and signaling pathway inhibitor can further improve recurrent and refractory MM remission rate and survival period, but now many of the new drugs still need more reasonable combination of traditional medicines, optimizing the dosing mode, improving the biocompatibility and reduce cost.